{"nctId":"NCT01164501","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment","startDateStruct":{"date":"2010-07"},"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency"],"count":741,"armGroups":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: Placebo"]},{"label":"BI 10773 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: BI 10773"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BI 10773","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated glomerular filtration rate of \\<90 ml/min.\n2. Male and female patients on diet and exercise regimen who are pre-treated with any antidiabetic therapy and are on the maximum tolerated dose which has been unchanged for 12 weeks prior to randomisation.\n3. HbA1c greater than or equal to 7.0% and less than or equal to 10.0% .\n4. Aged 18 years or above.\n5. Body Mass Index less than or equal to 45 kg/m2\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycaemia defined as \\>13.3 mmol/L after an overnight fast during placebo run-in.\n2. Impaired renal function, defined as an estimated glomerular filtration rate \\<15 ml/min.\n3. Renal impairment requiring any form of chronic dialysis.\n4. Requiring acute dialysis within three months prior to informed consent.\n5. Renal transplant recipient.\n6. Myocardial infarction, stroke or Transient Ischemic Attack within three months prior to informed consent.\n7. Indication of liver disease.\n8. Bariatric surgery within the past two years.\n9. Medical history of cancer.\n10. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell.\n11. Contraindications to pre-existing background antidiabetic therapy.\n12. Treatment with anti-obesity drugs.\n13. Current treatment with systemic steroids or change in dosage of thyroid hormones within six weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes.\n14. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and are not practising an acceptable method of birth control.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline in Patients With Mild or Moderate Renal Impairment","description":"Change from baseline in HbA1c after 24 weeks, for patients with mild or moderate renal impairment.\n\nNote adjusted means are provided.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.04"},{"groupId":"OG001","value":"-0.46","spread":"0.04"}]}]}]},{"type":"PRIMARY","title":"HbA1c Change From Baseline in Patients With Mild Renal Impairment","description":"Change from baseline in HbA1c after 24 weeks, for patients with mild renal impairment.\n\nNote adjusted means are provided.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.07"},{"groupId":"OG001","value":"-0.46","spread":"0.07"},{"groupId":"OG002","value":"-0.63","spread":"0.07"}]}]}]},{"type":"PRIMARY","title":"HbA1c Change From Baseline in Patients With Moderate Renal Impairment","description":"Change from baseline in HbA1c after 24 weeks, for patients with moderate renal impairment.\n\nNote adjusted means are provided.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.05"},{"groupId":"OG001","value":"-0.37","spread":"0.05"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hypoglycaemic Events","description":"Percentage of patients who experienced a hypoglycaemic event. A hypoglycaemic event was regarded as confirmed if it was documented as an adverse event with plasma glucose values \\<= 70 mg/dL (\\<=3.9mmol/L) measured or with a documentation that the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative action had been required.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"26.5","spread":null},{"groupId":"OG002","value":"27.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44,"n":319},"commonTop":["Hypoglycaemia","Urinary tract infection","Upper respiratory tract infection","Hyperglycaemia","Nasopharyngitis"]}}}